These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38415920)

  • 1. Lung clearance index (LCI
    Urquhart DS; Dowle H; Moffat K; Forster J; Cunningham S; Macleod KA
    Pediatr Pulmonol; 2024 May; 59(5):1449-1453. PubMed ID: 38415920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial.
    McNally P; Lester K; Stone G; Elnazir B; Williamson M; Cox D; Linnane B; Kirwan L; Rea D; O'Regan P; Semple T; Saunders C; Tiddens HAWM; McKone E; Davies JC;
    Am J Respir Crit Care Med; 2023 Nov; 208(9):917-929. PubMed ID: 37703083
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
    Nichols DP; Paynter AC; Heltshe SL; Donaldson SH; Frederick CA; Freedman SD; Gelfond D; Hoffman LR; Kelly A; Narkewicz MR; Pittman JE; Ratjen F; Rosenfeld M; Sagel SD; Schwarzenberg SJ; Singh PK; Solomon GM; Stalvey MS; Clancy JP; Kirby S; Van Dalfsen JM; Kloster MH; Rowe SM;
    Am J Respir Crit Care Med; 2022 Mar; 205(5):529-539. PubMed ID: 34784492
    [No Abstract]   [Full Text] [Related]  

  • 4. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor.
    De Vuyst R; Kam CW; McKinzie CJ; Esther CR
    Pediatr Pulmonol; 2024 Jul; 59(7):2051-2054. PubMed ID: 38629427
    [No Abstract]   [Full Text] [Related]  

  • 7. Triple Therapy for Cystic Fibrosis
    Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
    N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients.
    Klimeš F; Voskrebenzev A; Gutberlet M; Speth M; Grimm R; Dohna M; Hansen G; Wacker F; Renz DM; Dittrich AM; Vogel-Claussen J
    Eur Radiol; 2024 Jan; 34(1):80-89. PubMed ID: 37548691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.
    Burgel PR; Paillasseur JL; Durieu I; Reynaud-Gaubert M; Hamidfar R; Murris-Espin M; Danner-Boucher I; Chiron R; Leroy S; Douvry B; Grenet D; Mely L; Ramel S; Montcouquiol S; Burnet E; Ouaalaya EH; Sogni P; Da Silva J; Martin C;
    Ann Am Thorac Soc; 2024 Jul; 21(7):1053-1064. PubMed ID: 38579175
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with Cystic Fibrosis following liver transplantation: A systematic review.
    Testa I; Indolfi G; Brugha R; Verkade HJ; Terlizzi V
    J Cyst Fibros; 2024 May; 23(3):554-560. PubMed ID: 38614868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral lung effect of elexacaftor/tezacaftor/ivacaftor in adult cystic fibrosis.
    Stylemans D; Darquenne C; Schuermans D; Verbanck S; Vanderhelst E
    J Cyst Fibros; 2022 Jan; 21(1):160-163. PubMed ID: 33832855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis.
    Maher RE; Barry PJ; Emmott E; Jones AM; Lin L; McNamara PS; Smith JA; Lord RW
    J Cyst Fibros; 2024 Mar; 23(2):269-277. PubMed ID: 37951788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Evaluation of Bronchial Changes in Cystic Fibrosis Patients Undergoing Elexacaftor/Tezacaftor/Ivacaftor Therapy Using Lung MRI With Ultrashort Echo-Times.
    David M; Benlala I; Bui S; Benkert T; Berger P; Laurent F; Macey J; Dournes G
    J Magn Reson Imaging; 2024 Jul; 60(1):116-124. PubMed ID: 37861357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis.
    Di Gioia S; Lucca F; Venditto L; Sandri G; Tommasi N; Cipolli M; Molteni G
    Am J Otolaryngol; 2024; 45(3):104236. PubMed ID: 38417261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant.
    Young D; Bartlett LE; Guimbellot J; Milinic T; Burdis N; Gill ER; Lease ED; Goss CH; Kapnadak SG; Ramos KJ
    J Cyst Fibros; 2024 May; 23(3):545-548. PubMed ID: 37798159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?
    Terlizzi V
    J Cyst Fibros; 2024 Mar; 23(2):366-367. PubMed ID: 37838487
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.